Molecular profiling testing revealed that tumor tissue was ER+ (90%), amplified for ERBB2 (HER2/neu), PR+, programmed death ligand 1-positive (IHC; Sp142), MS, NTRK fusion negative, AR mutation positive, BRCA1 and BRCA2 negative, PIK3CA mutated, and PTEN mutation positive. The gene discussed is ERBB2; the disease is neoplasm.